Fukuda Denshi (6960) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
19 Aug, 2026Executive summary
Net sales rose 2.0% year-over-year to 30,985 million yen for the first quarter ending June 30, 2026.
Operating profit increased 9.9% year-over-year to 4,592 million yen, and ordinary profit grew 11.5% to 4,867 million yen.
Profit attributable to owners of parent was 3,079 million yen, up 8.8% year-over-year.
Comprehensive income surged 115.7% year-over-year to 6,920 million yen, driven by valuation gains on securities.
Financial highlights
Earnings per share for the quarter were 113.97 yen, up from 100.87 yen a year earlier.
Total assets increased to 229,264 million yen, and net assets rose to 191,845 million yen.
Shareholders' equity ratio remained strong at 83.7%.
Depreciation for the quarter was 3,095 million yen, up from 2,779 million yen in the prior year.
Outlook and guidance
Full-year forecast maintained: net sales of 142,000 million yen (+1.6%), operating profit of 25,500 million yen (+4.2%), and profit attributable to owners of parent of 17,700 million yen (+5.8%).
Earnings per share for the full year projected at 655.13 yen.
No revisions to dividend or business forecasts; annual dividend forecast is 230 yen per share.
Latest events from Fukuda Denshi
- Modest sales and profit growth, with FY2027 guidance signaling lower earnings and a compliance incident.6960
Q4 2026 - Slight YoY profit decline offset by strong comprehensive income and stable full-year outlook.6960
Q3 2026 - Net sales up 0.8% and operating profit steady, with segment shifts and stable full-year outlook.6960
Q2 2026 - Sales rose 4% year-over-year, but profits declined; full-year guidance and dividends unchanged.6960
Q1 2025 - First-half profits fell on lower sales, but full-year guidance and dividend plans remain unchanged.6960
Q2 2025 - Profits declined despite stable sales, with mixed segment performance and steady full-year outlook.6960
Q3 2025 - Slight declines in sales and profit, with FY2026 guidance indicating further contraction.6960
Q4 2025 - Profits declined despite stable sales; medical treatment and consumables segments showed growth.6960
Q1 2026